Company / R&D Expense
Insulet Corporation R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$301.1M
FY2025
5-year range
$132.3M / $301.1M
FY2021-FY2025
Trend
+37.1%
vs FY2024
Sector context
#25 of 110
Health Care
What the data says
Insulet Corporation's r&d expense of $301M is higher than 77% of companies in the Health Care sector (FY2025). R&D Expense has increased for 6 consecutive years, from $76M in FY2019 to $301M in FY2025.
Based on SEC 10-K filings.
$301M in FY2025 with a 5-year CAGR of +26.0%. Top quartile in the Health Care sector.
Improved from $205M to $301M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +27.1%
- 5-Year CAGR
- +26.0%
- 10-Year CAGR
- -
Sector benchmark
In line with sector averageTop 23% of 110This company $301.1M Sector average $298.2M
▼
In line with sector average
Key checks
Key Insights
- Insulet Corporation's r&d expense has grown for 6 consecutive years.
- 5-year CAGR of +26.0%, indicating consistent growth.
- In FY2025, r&d expense increased 37.1% year-over-year.
- Ranks #25 out of 110 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $301.1M | +37.1% |
| FY2024 | $219.6M | +7.1% |
| FY2023 | $205.0M | +39.6% |
| FY2022 | $146.8M | +11.0% |
| FY2021 | $132.3M | +39.6% |
| FY2020 | $94.8M | +25.2% |
| FY2019 | $75.7M | -20.1% |
| FY2018 | $94.8M | +25.2% |
| FY2017 | $75.7M | +35.9% |
| FY2016 | $55.7M | +28.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026